LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24..

加利福尼亚州拉霍亚——（商业新闻短讯）——Equillium，Inc.（纳斯达克：EQ），一家专注于开发治疗严重自身免疫性和炎症性疾病的新型疗法的临床阶段生物技术公司，今天宣布，预计将在2024年罗素年度重组结束时加入罗素Microcap指数，根据5月24日星期五发布的初步补充名单，该指数将于7月1日星期一的股市开放时生效。。

The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes..

截至4月30日星期二，罗素年度重组捕获了4000只最大的美国股票，按总市值排名。Russell Microcap指数的会员资格有效期为一年，意味着自动纳入适当的增长和价值风格指数。富时罗素指数主要通过客观、市值排名和风格属性来确定其罗素指数的成员资格。。

“We’re happy to be joining the Russell Microcap Index, paving the way for potential inclusion in a large number of funds that aim to mimic and benchmark the Russell indices,” said Bruce Steel, chief executive officer at Equillium. “This increased exposure can also highlight our recent Phase 2 alopecia areata data – indicating EQ101 was well-tolerated and clinically active – that will inform future development, as well as our partnership with Ono Pharmaceutical where we expect to delivery our final data package during the third quarter of this year.”.

Equillium首席执行官布鲁斯·斯蒂尔（BruceSteel）表示：“我们很高兴加入罗素微胶囊指数（RussellMicrocapIndex），为可能纳入大量旨在模仿和基准罗素指数的基金铺平了道路。”。“这种增加的暴露也可以突出我们最近的第二阶段斑秃数据-表明EQ101具有良好的耐受性和临床活性-这将为未来的发展以及我们与Ono Pharmaceutical的合作关系提供信息，我们预计在今年第三季度交付我们的最终数据包。”。

About Equillium

关于Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways.

Equillium是一家临床阶段的生物技术公司，利用对免疫生物学的深入了解，开发新的治疗方法，以治疗严重的自身免疫性和炎症性疾病，并满足高度未满足的医疗需求。该公司的管道由以下新型一流的免疫调节资产和针对免疫炎症途径的产品平台组成。

EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive results from a Phase 2 proof-of-concept clinical study of patients with alopecia areata in Australia and New Zealand by Equillium’s Australian subsidiary as the trial sponsor. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21; currently in pre-clinical development.

EQ101：靶向IL-2，IL-9和IL-15的选择性三特异性细胞因子抑制剂；最近，Equillium的澳大利亚子公司作为试验赞助商，宣布了澳大利亚和新西兰斑秃患者的2期概念验证临床研究的积极结果。EQ302：靶向IL-15和IL-21的口服递送的选择性双特异性细胞因子抑制剂；目前正在进行临床前开发。

The multi-cytokine platform: generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and announced positive data from a Phase 1b clinical study of patients with lupus/lupus nephritis in April 2024.

多细胞因子平台：产生合理设计的复合肽，其在共享受体水平选择性阻断关键细胞因子，靶向致病性细胞因子冗余和协同作用，同时保留非致病性信号传导。伊托珠单抗：一种靶向CD6-ALCAM信号通路的单克隆抗体，在调节效应T细胞中起着核心作用；目前正在急性移植物抗宿主病（aGVHD）患者的3期临床研究中进行评估，并于2024年4月宣布了狼疮/狼疮性肾炎患者1b期临床研究的阳性数据。

Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. (Ono), for the development and commercialization of itolizumab under an option and asset purchase agreement..

Equillium通过与Biocon Limited的独家合作关系获得了伊托珠单抗的权利，并与Ono Pharmaceutical Co.，Ltd.（Ono）建立了战略合作伙伴关系，根据期权和资产购买协议开发和商业化伊托珠单抗。。

For more information, visit www.equilliumbio.com.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

前瞻性声明

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate', “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

本新闻稿中关于非历史事实的声明是1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。前瞻性陈述可以通过使用诸如“预期”、“相信”、“可能”、“继续”、“预期”、“估计”、“可能”、“计划”、“展望”、“未来”和“项目”等词语以及预测或指示未来事件或趋势或不属于历史事项陈述的其他类似表达来识别。

These statements include, but are not limited to, statements regarding Equillium’s expectation that it will be included in the Russell Microcap Index and the timing for its inclusion, the inclusion of Equillium in the Russell Microcap Index will potentially lead to Equillium’s inclusion in a larger number of funds, increased exposure from inclusion in the Russell Microcap Index will highlight Equillium’s current programs, plans for developing EQ101 and the expected timeline for results from clinical studies, the timing for triggering Ono’s option period and receiving Ono’s option decision, and the potential benefits of Equillium’s product candidates.

这些声明包括但不限于关于Equillium期望将其纳入Russell Microcap指数及其纳入时间的声明，将Equillium纳入Russell Microcap指数将可能导致Equillium纳入更多基金，将Equillium纳入Russell Microcap指数的风险敞口增加将突出Equillium目前的计划，开发EQ101的计划以及临床研究结果的预期时间表，触发Ono期权期和接受Ono期权决定的时间，以及Equillium候选产品的潜在收益。

Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that Equillium will not be included in the Russell Microcap Index on the stated timeline or at all; the degree to which Equillium will realize the expected benefits from inclusion in the Russell Microcap Index, if all, Equillium’s ability to execute its plans and strategies; risks related to performing c.

由于此类声明存在风险和不确定性，其中许多不在Equillium的控制范围内，因此实际结果可能与此类前瞻性声明中明示或暗示的结果存在重大差异。导致前瞻性陈述不确定性的风险包括：在规定的时间表上，均分不包括在Russell Microcap指数中或根本不包括在内的风险；Equillium将在多大程度上实现纳入Russell Microcap指数的预期收益，如果有的话，Equillium执行其计划和策略的能力；与执行c相关的风险。